Candel Therapeutics, Inc. License Agreements
6 Contracts & Agreements
- Amendment to Exclusive License Agreement by and between Candel Therapeutics, Inc. and Periphagen, Inc., dated June 7, 2023 (Filed With SEC on August 10, 2023)
- Exclusive Patent License Agreement by and between Advantagene, Inc. and The Brigham and Womens Hospital, Inc. dated September 15, 2020 (Filed With SEC on July 16, 2021)
- Exclusive License Agreement by and between Advantagene, Inc. and Ventagen, LLC dated March 1, 2014 (Filed With SEC on July 16, 2021)
- Exclusive Patent License Agreement by and between Advantagene, Inc. and The Brigham and Womens Hospital, Inc. dated September 15, 2020 (Filed With SEC on June 25, 2021)
- Exclusive License Agreement by and between Advantagene, Inc., d/b/a Candel Therapeutics and Periphagen, Inc. dated December 9, 2019 (Filed With SEC on June 25, 2021)
- Exclusive License Agreement by and between Advantagene, Inc. and Ventagen, LLC dated March 1, 2014 (Filed With SEC on June 25, 2021)
